Determination of mitotane (o,p'-DDD) and its metabolites o,p'-DDA and o,p'-DDE in plasma by high-performance liquid chromatography

Therapeutic Drug Monitoring

Volumn 21, Issue 3, 1999, Pages 355-359

  Andersen, Anders ^a   Kasperlik Zaluska, Anna A ^b   Warren, David J ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b MEDICAL CENTER FOR POSTGRADUATE EDUCATION   (Poland)

Author keywords

Adrenocortical carcinoma; HPLC; Mitotane; O,p' DDA

Indexed keywords

1,1 (2,4' DICHLORODIPHENYL) 2,2 DICHLOROETHANE; 1,1 (2,4' DICHLORODIPHENYL)ACETIC ACID; ACETONE; DRUG METABOLITE; MITOTANE; PLASMA PROTEIN; UNCLASSIFIED DRUG;

ADRENAL CORTEX CARCINOMA; ADULT; AGED; ARTICLE; CASE REPORT; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG EFFICACY; DRUG METABOLISM; DRUG MONITORING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PRECIPITATION; PRIORITY JOURNAL; SAMPLING;

ADRENAL CORTEX NEOPLASMS; ADRENERGIC AGENTS; ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG STABILITY; FEMALE; HUMANS; LINEAR MODELS; MALE; MIDDLE AGED; MITOTANE;

EID: 0032967710     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199906000-00020     Document Type: Article

References (24)

1. Bergenstal DM, Hertz R, Lipsett MB, Moy RH. Chemotherapy of adrenocortical cancer with o,p′-DDD. Ann Intern Med 1960;53: 672-82.
2. Kasperlik-Zaluska AA, Migdalska BM, Zgliczynski S, Makowska AM. Adrenocortical carcinoma: a clinical study and treatment results of 52 patients. Cancer 1995;75:2587-91.
3. Haak HR, Hermans J, van de Velde CJH, et al. Optimal treatment of adrenocortical carcinoma with mitotane: results in a consecutive series of 96 patients. Br J Cancer 1994;69:947-51.
4. van Slooten H, Moolenaar AJ, van Seters AP, Smeenk D. The treatment of adrenocortical carcinoma with o,p′-DDD: prognostic implications of serum level monitoring. Eur J Cancer Clin Oncol 1984;20:47-53.
5. Komely E, Schlaghecke R. Complete remission of metatasized adrenocortical carcinoma under o,p′-DDD. Exp Clin Endocrinol 1994;102:50-3.
6. Lim MCL, Tan YO, Chong PY, Cheah JS. Treatment of adrenal conical carcinoma with mitotane: outcome and complications. Ann Acad Med Singapore 1990;19:540-4.
7. Hajjar RA, Hickey RC, Samaan NA. Adrenal cortical carcinoma: a study of 32 patients. Cancer 1975;35:549-54.
8. Carpenter PC. Mitotane failure in adrenoconical cancer: where next? Cancer 1993;71:2900-1.
9. Vassilopoulou-Sellin R, Guinee VF, KJein MJ, et al. Impact of adjuvant mitotane on the clinical course of patients with adrenoconical cancer. Cancer 1993;71:3119-23.
10. Wooten MD, King DK. Adrenal conical carcinoma. Epidemiology and treatment with mitotane and a review of the literature. Cancer 1993;72:3145-55.
11. Martz F, Straw JA. The in vitro metabolism of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2,2-dichloroethane (o,p′-DDD) by dog adrenal mitochondria and metabolite covalent binding to mitochondrial macromolecules. Drug Metab Dispos 1977;5:482-6.
12. Martz F, Straw JA. Metabolism and covalent binding of 1-(o-chlorophenyl)-1-(p-chlorophenyl)-2.2-dichloroethane (o,p′-DDD). Drug Metab Dispos 1980;8:127-30.
13. Cai W, Counsell RE, Djanegara T, Schteingart DE, Sinsheimer JE, Wotring LL. Metabolic activation and binding of mitotane in adrenal cortex homogenates. J Pharm Sci 1995;84:134-8.
14. Cai W, Benitez R, Counsell RE, et al. Bovine adrenal cortex transformations of mitotane (1-(2-chlorophenyl)-1-(4-chlorophenyl)-2,2-dichloroethane; o,p′-DDD) and its p,p′- and m,p′-isomers. Biochem Pharmacol 1995;49:1483-9.
15. Hogan TF, Citrin DL, Johnson BM, Nakamura S, Davis TE, Borden EC. o,p′-DDD (Mitotane) therapy of adrenal conical carcinoma. Cancer 1978;42:2177-81.
16. Inouye M, Mio T, Sumino K. Use of GC/MS/SIM for rapid determination of plasma levels of o,p′-DDD, o,p′-DDE and o,p′-DDA. Clin Chim Acta 1987;170:305-14.
17. Sinsheimer JE, Counsell RE, Cai W, et al. Gas chromatographic-electron capture determination of 2,4′-dichlorodiphenylacetic acid from in vitro adrenal transformations of mitotane and its analogs. J Pharm Biomed Anal 1996;14:861-6.
18. Andersen A, Warren DJ, Nome O, Vesterhus L, Slørdal L. A High-pressure liquid chromatographic method for measuring mitotane (1,1-(o,p′-dichlorodiphenyl)-2,2-dichloroethane) and its metabolite 1,1-(o,p′-dichlorodiphenyl)-2.2-dichloroethene in plasma. Ther Drug Monit 1995;17:526-31.
19. Moolenaar AJ, Niewint JWM, Oei IT. Estimation of o,p′-DDD in plasma by gas-liquid chromatography. Clin Chim Acta 1977;76: 213-8.
20. Ware GW, Crosby DG, Giles JW. Photodecomposition of DDA. Arch Environm Contam Toxicol 1980;9:135-46.
21. Khorram-Manesh, Ahlman H, Jansson S, et al. Adrenocortical carcinoma: surgery and mitotane for treatment and steroid profiles for follow-up. World J Surg 1998;22:605-12.
22. Moolenaar AJ, van Slooten H, van Seters AP, Smeenk D. Blood levels of o,p′-DDD following administration in various vehicles after a single dose and during long-term treatment. Cancer Chemother Pharmacol 1981;7:51-1.
23. Lund BO, Klasson-Wehler E, Brandt I. o,p′-DDD in the mouse lung: selective uptake, covalent binding and effect on drug metabolism. Chem Biol Interact 1986;60:129-11.
24. Boven E, Vermerken JB, van Slooten H, Pinedo HM. Complete response of metastasized adrenal cortical carcinoma with o,p′-DDD. Cancer 1984;53:26-9.